Principal Investigator
Amer Beitinjaneh
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20231360
Clinical Trial Summary
A Phase I, Multicenter Study of CD4- directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with Relapsed or Refractory CD4+ Lymphoid Hematological Malignancies
Phase
Phase I
Funding Agency/Sponsor
Institutional
Disease
Lymphoma
Contact Information
Phone Number
305-243-2647